ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0642

Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics

Lihi Eder1, Shadi Akhtari2, Dana Jerome1, Jacob Udell1, Patrick Lawler1, Paula Harvey3 and Bindee Kuriya4, 1University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, University of Toronto, North York, ON, Canada, 3Women's College Hospital, University of Toronto, Toronto, ON, Canada, 4University of Toronto - Toronto, Toronto, ON, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, rheumatoid arthritis, risk factors, Spondyloarthropathies

Session Information

Date: Sunday, November 7, 2021

Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Cardio-metabolic abnormalities are common in patients with inflammatory arthritis (IA) but tend to be under-recognized and under-treated. We aimed to compare the prevalence and risk factors for cardio-metabolic abnormalities between patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

Methods: Consecutive patients enrolled in the University of Toronto Cardio-Rheumatology Network from 2017 to 2020 were analyzed. This is a primary prevention program that uses structured clinical, laboratory and multimodal imaging to diagnose and treat cardiovascular disease (CVD). Patients with a rheumatologist-confirmed diagnosis of RA, PsA or AS and no known CVD were evaluated. Information about IA diagnosis, medications and comorbidities was recorded. Each patient was evaluated by a cardiologist focusing on CVD risk assessment. We evaluated the prevalence of previously recorded and newly recognized cardio-metabolic risk factors including hypertension, dyslipidemia, obesity and diabetes. The prevalence of these abnormalities was compared between IA diagnoses. Regression models were used to assess the association between diagnosis and cardio-metabolic abnormalities after adjusting for demographics, smoking, BMI, measures of disease activity and medications.

Results: A total of 376 patients (219 RA, 124 PsA, 33 AS) were assessed (mean age 59±10.4 years, 69.7% female). Hypertension was reported in 33.2%, dyslipidemia in 26.8%, diabetes mellitus in 8.8% and overweight/obesity in 68.7%. Newly diagnosed dyslipidemia (elevated total cholesterol), elevated blood pressure and diabetes occurred in 40.3%, 14.8% and 1.5% of all patients (Figure 1). A total of 32% patients required a change or initiation of medications for their cardio-metabolic abnormalities (21.7% lipid-lowering therapy, 13.4% aspirin, 10.9% anti-hypertension therapy). Patients with PsA had the highest prevalence of cardio-metabolic abnormalities including dyslipidemia, obesity and hypertension (Figure 2). Having hypertension (prior or new diagnosis), elevated levels of triglycerides, non-HDL cholesterol, total cholesterol and BMI were associated with PsA vs. RA after adjusting for potential confounders (Figure 3). No significant association was found between cardio-metabolic abnormalities and AS vs. PsA or RA.

Conclusion: Dedicated cardio-rheumatology clinics have improved CVD screening and management in an IA population. The burden of cardio-metabolic abnormalities is elevated in PsA and suggests that tailored strategies to reduce adverse CVD events are particularly needed in this subgroup.

Figure 1 – The prevalence of previously and newly diagnosed cardiovascular risk factors

Figure 2 – Prevalence of cardio-metabolic risk factors in patients with inflammatory arthritis by disease category

Figure 3 – The Association between Disease Category and Cardiovascular Risk Factors by adjusted regression coefficients or Odds Ratio (95% Confidence interval)*


Disclosures: L. Eder, Pfizer, 1, 5, UCB, 5, Abbvie, 1, 5, Novartis, 2, Eli Lily, 1, 5, Fluidigm, 5, 12, Family member - employee, Janssen, 5; S. Akhtari, None; D. Jerome, Abbvie, 1, Novartis, 1, celltrion, 1, Gilead, 1, Lilly, 1; J. Udell, Boehringer-Ingelheim, 1, 5, Bayer, 5, Novartis, 1, 5, Sanofi, 1, 5, 6, Janssen, 5; P. Lawler, Novartis, 2; P. Harvey, None; B. Kuriya, None.

To cite this abstract in AMA style:

Eder L, Akhtari S, Jerome D, Udell J, Lawler P, Harvey P, Kuriya B. Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-risk-factors-for-cardio-metabolic-abnormalities-in-patients-with-inflammatory-arthritis-attending-cardio-rheumatology-primary-prevention-clinics/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-risk-factors-for-cardio-metabolic-abnormalities-in-patients-with-inflammatory-arthritis-attending-cardio-rheumatology-primary-prevention-clinics/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology